Efficacy of Urinary Follicle-Stimulating Hormone (FSH) Among Poor Responders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00677573
Recruitment Status : Unknown
Verified May 2008 by German Hospital, Istanbul.
Recruitment status was:  Not yet recruiting
First Posted : May 14, 2008
Last Update Posted : May 14, 2008
Bahceci Women Health Care Center
Information provided by:
German Hospital, Istanbul

Brief Summary:
We proposed to compare outcomes in women with DOR undergoing ART with rec-FSH + u-HMH with those with u-FSH only in GnRH antagonist protocols.

Condition or disease Intervention/treatment Phase
Infertility Drug: Fostimon Not Applicable

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Urinary Purified Follicle-Stimulating Hormone (FSH) and Rec-FSH Among Poor Responders Undergoing Ovarian Stimulation With GnRH Antagonist
Study Start Date : May 2008
Estimated Primary Completion Date : October 2008
Estimated Study Completion Date : November 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: UrFSH Drug: Fostimon
450 IU for 4 days then adjusted

Primary Outcome Measures :
  1. pregnancy rate per embryo transfer [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. number of oocytes retrieved [ Time Frame: per patient ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 44 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • At least one trial with adequate ovarian stimulation resulted by 4 or less oocytes retrieval.

Exclusion Criteria:

  • High responder patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00677573

Contact: Ulun Ulug, M.D. 90-21-2293-2150 ext 14111
Contact: Mustafa Bahceci, M.D 90-21-2230-0809

Alman Hastanesi Not yet recruiting
İstanbul, Turkey
Contact: Haluk Toygarlı, M.D.    90-21-2293-2150      
Principal Investigator: ulun ulug, M.D.         
Sub-Investigator: mustafa bahceci, M.D.         
Sub-Investigator: enver kurt, M.D.         
Sponsors and Collaborators
German Hospital, Istanbul
Bahceci Women Health Care Center

Responsible Party: German Hospital, Istanbul Identifier: NCT00677573     History of Changes
Other Study ID Numbers: ughno1
First Posted: May 14, 2008    Key Record Dates
Last Update Posted: May 14, 2008
Last Verified: May 2008

Keywords provided by German Hospital, Istanbul:
poor responder
GnRH antagonist

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female
Follicle Stimulating Hormone
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs